Skip to main content

Advertisement

SpringerLink
Log in

Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?

  • Benign Prostatic Hyperplasia (K McVary, Section Editor)
  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Contrary to the previous dogma that prostatic growth is directly proportional to testosterone levels, emerging research has suggested a lack of testosterone may be a risk factor for lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Within this review article, we have demonstrated the current understanding of the physiology of hypogonadism and its interplay with prostatic and lower urinary tract physiology. The current evidence suggests that not only does testosterone replacement therapy (TRT) not worsen LUTS, but that hypogonadism itself is an important risk factor for LUTS/BPH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment-the QUALIPROST study. Int Urol Nephrol 2016.

  2. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410–5.

    Article  CAS  PubMed  Google Scholar 

  3. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59:245–50.

    Article  PubMed  Google Scholar 

  4. Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male: Off J Int Soc Study Aging Male. 2008;11:51–5.

    Article  CAS  Google Scholar 

  5. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol. 2011;52:657–63. This is a well-written review article that highlights the effect of hypogonadism on LUTS. Now slightly dated with more evidence out currently, but sets forth a strong foundation of knowledge current studies are based on.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab. 2004;89:5920–6. This paper uses the Massachusetts Male Aging Study, an observatoinal cohort study of health in a population-based random sample of men between the ages of 40 and 70 years old. Data on androgen deficiency was collected in 1691 men, making it a large sample of healthy men fromw which to draw prevalance information.

    Article  CAS  PubMed  Google Scholar 

  7. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–99.

    Article  CAS  PubMed  Google Scholar 

  8. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116:2694–701.

    Article  CAS  PubMed  Google Scholar 

  9. Schubert M, Jockenhovel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J Endocrinol Investig. 2005;28:23–7.

    Article  CAS  Google Scholar 

  10. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2670–7.

    CAS  PubMed  Google Scholar 

  11. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578–83.

    CAS  PubMed  Google Scholar 

  12. AndroGel (testosterone gel) 1.62% Product Insert. http://www.rxabbvie.com/pdf/androgel1_62_PI.pdf. Accessed 26 Feb 2016.

  13. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Welliver Jr RC, Wiser HJ, Brannigan RE, Feia K, Monga M, Kohler TS. Validity of midday total testosterone levels in older men with erectile dysfunction. J Urol. 2014;192:165–9.

    Article  CAS  PubMed  Google Scholar 

  15. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589–98.

    Article  CAS  PubMed  Google Scholar 

  16. Liu PY, Beilin J, Meier C, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab. 2007;92:3599–603.

    Article  CAS  PubMed  Google Scholar 

  17. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86:724–31.

    Article  CAS  PubMed  Google Scholar 

  18. Keast JR. Plasticity of pelvic autonomic ganglia and urogenital innervation. Int Rev Cytol. 2006;248:141–208.

    Article  CAS  PubMed  Google Scholar 

  19. Rosenzweig BA, Bolina PS, Birch L, Moran C, Marcovici I, Prins GS. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn. 1995;14:87–96.

    Article  CAS  PubMed  Google Scholar 

  20. Salmi S, Santti R, Gustafsson JA, Makela S. Co-localization of androgen receptor with estrogen receptor beta in the lower urinary tract of the male rat. J Urol. 2001;166:674–7.

    Article  CAS  PubMed  Google Scholar 

  21. Takyu S. Effects of testosterone on the autonomic receptor-mediated function in lower urinary tract from male rabbits. Nihon Hinyokika Gakkai Zasshi Jpn J Urol. 1993;84:330–8.

    CAS  Google Scholar 

  22. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012;61:994–1003.

    Article  CAS  PubMed  Google Scholar 

  23. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177:1401–7.

    Article  CAS  PubMed  Google Scholar 

  24. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008;53:1236–44.

    Article  CAS  PubMed  Google Scholar 

  25. Lythgoe C, McVary KT. The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013;14:585–94.

    Article  PubMed  Google Scholar 

  26. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997;33:1–8.

    Article  CAS  PubMed  Google Scholar 

  27. Zhao C, Kim SH, Lee SW, et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011;107:1943–7.

    Article  PubMed  Google Scholar 

  28. Mitterberger M, Pallwein L, Gradl J, et al. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int. 2007;99:831–5.

    Article  PubMed  Google Scholar 

  29. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br J Urol. 1998;82 Suppl 1:26–33.

    Article  PubMed  Google Scholar 

  30. Brousil P, Shabbir M, Zacharakis E, Sahai A. PDE-5 inhibitors for BPH-associated LUTS. Curr Drug Targets. 2015;16:1180–6.

    Article  CAS  PubMed  Google Scholar 

  31. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 2002;167:948–51.

    Article  CAS  PubMed  Google Scholar 

  32. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–20. This is an excellent paper detailing the current evidence on testosterone’s effects on prostatic growth. The paper goes cites numerous studies which indicate androgen receptor saturation at low levels of T, thus providing the argument for the saturation model of prostatic growth.

    Article  PubMed  Google Scholar 

  33. Moore A, Butcher MJ, Kohler TS. Testosterone replacement therapy on the natural history of prostate disease. Curr Urol Rep. 2015;16:51.

    Article  PubMed  Google Scholar 

  34. St Sauver JL, Jacobson DJ, McGree ME, et al. Associations between longitudinal changes in serum estrogen, testosterone, and bioavailable testosterone and changes in benign urologic outcomes. Am J Epidemiol. 2011;173:787–96.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose–response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–81.

    CAS  PubMed  Google Scholar 

  36. Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159:441–3. Thirty-one healthy males between the ages of 21 to 39 years old were supplemented randomly with either 100,250, or 500 mg of testosterone once weekly for 15 weeks. Over this time period, despite significant increases in total and free T (reaching total T levels all the way to 1994 ± 60 ng/dL in the 500 mg dosage group), there was no change in serum or semen PSA, or prostate volume as measured by TRUS.

    Article  CAS  PubMed  Google Scholar 

  37. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39–52. A double-blind, randomized, placebo controlled study of 237 healthy men between the ages of 60 and 80 years old with total T levels ≤ 13.7 nmol/L were randomized to receive 80 mg of testosterone undecenoate or a placebo twice daily for 6 months. Men receiving testosterone had increased lean body mass and decreased fat mass. Prostate volume, PSA, or IPSS score did not change in men receiving testosterone.

    CAS  PubMed  Google Scholar 

  38. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678–88.

    Article  CAS  PubMed  Google Scholar 

  39. Nair KS, Rizza RA, O’Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006;355:1647–59.

    Article  CAS  PubMed  Google Scholar 

  40. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40–80 years. Eur J Endocrinol / Eur Fed Endocr Soc. 2003;149:583–9.

    Article  CAS  Google Scholar 

  41. Crawford ED, Wilson SS, McConnell JD, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006;175:1422–6. discussion 6–7.

    Article  CAS  PubMed  Google Scholar 

  42. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150:351–8. This is a prospective cohort study of 198 outpatient men, which found no correlation of AUA-SS with uroflowmetry, post-void residual, prostate size, and degree of bladder trabeculation. Instead, symptom severity was strongly correlated with overall health.

    CAS  PubMed  Google Scholar 

  43. Castro JE, Griffiths HJ, Shackman R. Significance of signs and symptoms in benign prostatic hypertrophy. Br Med J. 1969;2:598–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kohn TP, Mata DA, Ramasamy R, Lipshultz LI. Effects of testosterone replacement therapy on lower urinary tract symptoms: a systematic review and meta-analysis. Eur Urol 2016. This is very recent systematic review and meta-analysis of the available evidence on the effects of testosterone replacement therapy on lower urinary tract symptoms. The study included 14 trials of 2029 patients and found that changes in IPSS were similar between men receiving TRT vs placebo, thus suggesting that TRT does not worsen LUTS.

  45. Cui Y, Zhang Y. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Eur Urol. 2013;64:811–22.

    Article  CAS  PubMed  Google Scholar 

  46. Saad F, Gooren L, Haider A, Yassin A. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007;53:353–7.

    Article  CAS  PubMed  Google Scholar 

  47. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11:1567–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA

    Wesley Baas & Tobias S. Köhler

Authors
  1. Wesley Baas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias S. Köhler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias S. Köhler.

Ethics declarations

Conflict of Interest

Wesley Baas and Tobias S. Köhler declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Benign Prostatic Hyperplasia

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baas, W., Köhler, T.S. Testosterone Replacement Therapy and BPH/LUTS. What is the Evidence?. Curr Urol Rep 17, 46 (2016). https://doi.org/10.1007/s11934-016-0600-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11934-016-0600-8

Keywords

Search

Navigation